Apollo Endosurgery stock price, funding rounds, valuation and financials

Apollo Endosurgery has raised $186.83 m in total funding. Apollo Endosurgery annual revenue was $50.71 m in FY 2019
View Company

$5.6 M

Apollo Endosurgery Revenue Q2, 2020
Apollo Endosurgery Gross profit (Q2, 2020)2.4 M
Apollo Endosurgery Gross profit margin (Q2, 2020), %43%
Apollo Endosurgery Net income (Q2, 2020)-6.3 M
Apollo Endosurgery EBIT (Q2, 2020)-4.3 M
Apollo Endosurgery Cash, 30-Jun-202019.1 M

Apollo Endosurgery Funding

Summary Metrics

Founding Date

2006

Apollo Endosurgery total Funding

$186.8 m

Apollo Endosurgery latest funding size

$22 m

Time since last funding

5 years ago

Apollo Endosurgery investors

UT Horizon Fund, HIG Capital
Apollo Endosurgery's latest funding round in November 2015 was reported to be $22 m. In total, Apollo Endosurgery has raised $186.8 m

Apollo Endosurgery Capital Raised

Embed Graph

Apollo Endosurgery Income Statement

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

9.4m6.7m8.0m5.1m1.6m64.9m64.3m60.9m50.7m

Cost of goods sold

25.3m24.6m27.7m25.0m

Gross profit

39.6m39.7m33.2m25.7m

Gross profit Margin, %

61%62%55%51%

Sales and marketing expense

31.8m32.9m32.8m28.7m

R&D expense

9.7m8.2m11.3m18.1m8.5m7.8m8.3m12.2m10.4m

General and administrative expense

3.4m4.1m4.2m4.8m3.9m13.6m13.7m13.4m13.6m

Operating expense total

13.1m12.2m15.6m22.9m12.5m60.4m62.2m73.3m49.2m

Depreciation and amortization

7.2m7.2m7.1m2.1m

EBIT

(3.7m)(5.6m)(7.6m)(17.8m)(10.9m)(20.8m)(22.4m)(40.1m)(23.5m)

EBIT margin, %

(40%)(83%)(95%)(350%)(679%)(32%)(35%)(66%)(46%)

Interest expense

595.9k2.8m1.0m1.3m18.2m4.5m4.1m4.1m

Pre tax profit

(40.8m)(27.0m)(45.6m)(27.2m)

Income tax expense

387.0k304.0k191.0k275.0k

Net Income

(3.1m)(2.8m)(6.6m)(16.6m)(10.0m)(41.2m)(27.3m)(45.8m)(27.4m)

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

1.5m1.8m2.8m1.3m1.4m1.1m2.0m2.6m1.7m1.3m1.1m783.9k747.6k61.3k9.6k9.2k23.8k14.6m17.1m16.5m15.7m7.3m6.7m13.2m14.3m11.3m10.7m5.6m

Cost of goods sold

5.1m6.6m6.0m6.6m6.0m7.1m5.8m5.1m3.2m

Gross profit

9.5m10.5m10.5m9.2m7.2m7.2m5.4m5.6m2.4m

Gross profit Margin, %

65%61%64%58%55%50%48%53%43%

Sales and marketing expense

8.4m8.6m8.0m9.2m7.7m7.8m6.5m6.3m2.3m

R&D expense

1.4m1.7m3.1m1.5m1.7m1.6m2.8m3.4m3.7m4.6m3.6m2.8m2.9m1.4m991.9k935.6k538.1k2.0m2.3m2.2m2.5m3.4m2.7m2.1m2.1m1.8m

General and administrative expense

794.2k774.1k881.9k872.9k1.1m1.0m1.1m976.7k1.2m1.1m1.0m1.1m1.1m858.0k963.5k1.7m1.5m4.2m3.2m2.9m3.3m3.7m3.3m3.2m3.3m2.2m

Operating expense total

2.2m2.5m4.0m2.4m2.8m2.6m3.9m4.3m4.8m5.7m4.7m3.8m4.0m2.3m2.0m2.7m2.1m16.3m16.0m14.8m16.8m9.8m14.4m12.3m12.3m6.7m

Depreciation and amortization

1.8m1.8m1.8m1.8m553.0k528.0k510.0k496.0k490.0k

EBIT

(632.3k)(701.0k)(1.2m)(1.1m)(1.4m)(1.5m)(1.9m)(1.8m)(3.1m)(4.3m)(3.6m)(3.0m)(3.2m)(2.2m)(1.9m)(2.7m)(3.7m)(6.8m)(5.5m)(4.3m)(7.6m)(2.5m)(7.2m)(6.9m)(6.7m)(4.3m)

EBIT margin, %

(41%)(39%)(44%)(81%)(95%)(133%)(96%)(70%)(180%)(325%)(321%)(386%)(432%)(3635%)(20252%)(28789%)(15553%)(47%)(32%)(26%)(48%)(19%)(50%)(61%)(62%)(76%)

Interest expense

2.0m1.8m1.9m433.3k252.1k227.0k550.0k750.4k200.0k600.0k400.0k1.5m1.1m1.0m960.0k959.0k669.0k1.2m1.2m1.3m

Pre tax profit

(8.2m)(6.8m)(4.8m)(8.1m)(2.8m)(8.8m)(8.6m)(10.2m)(6.2m)

Income tax expense

50.0k63.0k55.0k58.0k51.0k80.0k43.0k6.0k

Net Income

1.4m1.1m645.9k(646.6k)(1.1m)(1.2m)(1.4m)(2.5m)(3.3m)(3.7m)(3.2m)(2.8m)(2.6m)(2.2m)(1.9m)(2.7m)(3.7m)(8.2m)(6.9m)(4.9m)(8.1m)(2.8m)(8.8m)(8.7m)(10.3m)(6.3m)

Apollo Endosurgery Balance Sheet

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

14.4m24.6m11.9m17.3m8.9m19.1m30.5m24.0m29.9m

Accounts Receivable

1.3m233.8k1.3m727.2k7.0k10.5m11.7m11.4m9.2m

Prepaid Expenses

331.8k307.9k292.5k413.3k357.3k1.0m2.8m3.0m

Inventories

12.2m14.3m9.9m8.9m

Current Assets

16.1m25.2m13.5m18.4m9.3m43.6m57.6m48.1m51.0m

PP&E

176.1k253.6k211.4k221.1k149.3k6.9m6.9m5.9m6.6m

Goodwill

6.8m6.8m5.3m5.3m

Total Assets

17.9m27.2m15.7m21.0m11.6m102.1m109.1m74.5m74.6m

Accounts Payable

2.2m1.0m2.0m2.9m294.0k5.1m18.3m15.3m9.9m

Short-term debt

133.1k28.4m9.5m34.4m

Current Liabilities

10.1m8.6m3.5m4.3m1.1m20.3m25.8m24.4m52.8m

Long-term debt

39.4m33.3m21.2m19.7m

Total Debt

133.1k39.4m33.3m21.2m54.1m

Total Liabilities

17.3m12.2m5.7m5.1m1.1m59.7m59.1m45.6m72.5m

Common Stock

60.6k13.1k13.4k19.2k33.1k17.0k22.0k21.0k

Additional Paid-in Capital

40.7m57.8m59.4m81.8m86.5m190.7m225.1m249.1m250.6m

Retained Earnings

(40.2m)(42.9m)(49.5m)(66.0m)(76.0m)(149.7m)(177.0m)(222.8m)(250.2m)

Total Equity

629.0k14.9m10.0m15.8m10.5m42.4m49.9m28.8m2.1m

Debt to Equity Ratio

0.9 x0.7 x0.7 x

Debt to Assets Ratio

0.4 x0.3 x0.3 x

Financial Leverage

28.5 x1.8 x1.6 x1.3 x1.1 x2.4 x2.2 x2.6 x35.1 x

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

18.7m15.9m17.8m18.2m16.0m20.5m17.5m14.9m16.1m14.3m20.5m12.7m11.9m11.6m7.0m4.7m3.3m8.3m5.3m34.6m22.3m30.0m22.9m35.0m23.2m19.1m

Accounts Receivable

869.2k1.9m3.4m642.5k372.5k228.1k382.3k622.2k2.7m1.3m2.1m1.4m731.9k56.0k9.6k9.2k24.9k10.0m12.8m12.3m11.9m10.6m11.2m8.9m7.5m5.7m

Prepaid Expenses

95.8k439.6k188.7k129.3k286.1k217.1k194.5k261.0k445.6k418.0k1.7m431.0k297.1k193.5k269.5k614.2k698.8k2.1m1.9m1.1m1.3m3.3m3.1m3.4m3.1m3.0m

Inventories

11.7m11.4m12.8m15.4m10.4m10.6m10.8m10.2m11.0m

Current Assets

19.6m18.2m21.4m19.0m16.7m21.0m18.1m15.8m19.3m16.0m24.2m14.5m12.9m11.8m7.3m5.3m4.0m32.1m31.4m60.8m50.9m54.3m47.8m58.1m44.1m38.8m

PP&E

173.8k187.7k179.5k233.2k275.2k244.2k249.1k226.9k279.5k260.9k237.2k219.6k196.4k172.7k126.7k106.0k6.6m6.8m7.0m6.9m8.0m7.4m7.0m

Goodwill

6.8m6.8m6.8m6.8m5.3m5.3m5.3m5.3m5.3m

Total Assets

21.3m20.0m23.3m21.0m18.8m23.0m20.2m18.0m21.6m18.4m26.7m17.1m15.4m14.3m9.7m7.1m4.0m88.6m86.2m114.0m100.6m82.3m74.7m84.2m66.7m60.1m

Accounts Payable

569.4k672.1k1.0m759.5k918.9k836.0k1.0m2.1m2.6m2.5m2.6m2.0m1.7m1.2m431.1k462.7k894.6k6.4m18.1m16.2m18.8m8.1m9.3m10.2m9.5m7.2m

Short-term debt

26.6m30.3m34.5m5.4m

Current Liabilities

8.7m12.8m10.5m10.5m9.5m6.0m5.1m4.4m3.9m3.5m3.4m3.1m2.7m2.1m906.1k800.8k1.4m21.2m25.1m24.0m25.7m19.6m21.4m20.3m52.6m19.1m

Long-term debt

32.9m33.0m33.2m33.1m33.9m35.3m54.0m19.5m51.5m

Total Debt

32.9m33.0m59.8m63.4m33.3m31.0m33.9m33.9m34.3m54.0m56.9m

Total Liabilities

18.1m15.6m16.1m14.3m13.0m9.2m7.5m7.6m6.3m5.3m4.7m3.8m2.7m2.1m906.1k800.8k1.4m54.1m58.1m57.2m58.8m56.7m56.6m74.3m72.2m70.7m

Common Stock

60.5k60.5k73.7k73.7k10.5k13.1k13.1k13.1k15.3k15.6k19.2k19.4k25.8k31.1k33.1k2.4k2.4k11.0k11.0k17.0k17.0k22.0k22.0k21.0k21.0k21.0k

Additional Paid-in Capital

40.4m40.6m46.7m46.8m47.0m58.0m58.2m58.4m68.1m69.6m81.6m82.1m84.2m85.8m86.7m86.9m87.0m190.8m191.0m224.9m225.5m249.4m249.8m250.2m251.5m252.0m

Retained Earnings

(37.3m)(36.2m)(39.5m)(40.2m)(41.3m)(44.2m)(45.5m)(48.1m)(52.8m)(56.5m)(59.7m)(68.8m)(71.4m)(73.7m)(78.0m)(80.7m)(84.4m)(157.9m)(164.8m)(169.7m)(185.2m)(225.5m)(234.3m)(243.0m)(260.4m)(266.7m)

Total Equity

3.2m4.4m7.2m6.7m5.8m13.9m12.7m10.4m15.4m13.1m22.0m13.3m12.8m12.2m8.8m6.3m2.7m34.5m28.1m56.8m41.8m25.5m18.0m9.9m(5.5m)(10.6m)

Debt to Equity Ratio

1.3 x1.9 x3.4 x

Debt to Assets Ratio

0.4 x0.5 x0.4 x

Financial Leverage

6.7 x4.5 x3.2 x3.1 x3.2 x1.7 x1.6 x1.7 x1.4 x1.4 x1.2 x1.3 x1.2 x1.2 x1.1 x1.1 x1.5 x2.6 x3.1 x2 x2.4 x3.2 x4.1 x8.5 x-12.2 x-5.7 x

Apollo Endosurgery Cash Flow

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(3.1m)(2.8m)(6.6m)(16.6m)(10.0m)(41.2m)(27.3m)(45.8m)(27.4m)

Depreciation and Amortization

142.0k187.5k196.2k216.1k467.0k

Accounts Receivable

14.1m1.1m(1.1m)582.9k720.2k(426.0k)(916.0k)(162.0k)1.9m

Inventories

(3.1m)(2.8m)3.0m872.0k

Accounts Payable

1.2m(839.6k)(179.4k)1.1m(3.0m)523.0k4.7m(1.3m)(2.1m)

Cash From Operating Activities

8.1m(8.3m)(13.1m)(15.2m)(11.9m)(12.9m)(13.3m)(23.1m)(25.6m)

Purchases of PP&E

(134.2k)(154.8k)(44.7k)(105.6k)(21.1k)(1.0m)(1.6m)(2.0m)(805.0k)

Cash From Investing Activities

(489.0k)(344.3k)(391.1k)(535.9k)(291.2k)(2.2m)(2.1m)7.1m1.0m

Long-term Borrowings

(11.2m)(7.0m)(12.5m)(21.7m)

Cash From Financing Activities

34.1k18.9m770.8k21.2m3.8m12.6m26.7m9.7m30.5m

Net Change in Cash

7.6m10.2m(12.8m)5.4m(8.4m)(6.4m)5.9m

Interest Paid

5.8m3.8m3.8m3.5m

Income Taxes Paid

1.6k1.6k1.6k1.6k318.0k274.0k98.0k328.0k

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(275.8k)854.5k645.9k(720.0)(1.1m)(1.2m)(2.6m)(5.2m)(3.3m)(7.0m)(10.2m)(2.8m)(5.4m)(7.7m)(1.9m)(4.6m)(8.3m)(8.2m)(15.1m)(20.0m)(8.1m)(17.7m)(27.4m)(2.8m)(11.6m)(20.2m)(10.3m)(16.5m)

Depreciation and Amortization

37.2k65.8k21.5k47.2k75.0k42.0k129.0k161.5k35.9k98.9k167.0k70.6k142.4k262.3k45.4k672.3k135.1k

Accounts Receivable

14.5m13.5m(2.1m)692.1k962.1k5.7k(148.5k)(388.4k)(1.4m)(3.5k)(748.9k)(715.6k)(4.8k)671.2k(2.6k)(2.3k)(17.9k)658.0k(2.0m)(1.4m)62.0k(90.0k)1.1m790.0k117.0k2.1m1.4m3.3m

Inventories

514.0k653.0k(729.0k)(1.2m)(1.0m)439.0k(502.0k)(659.0k)(1.0m)(1.5m)(2.3m)

Accounts Payable

(917.9k)(884.6k)(1.1m)(1.3m)(1.3m)(2.0m)(1.4m)(271.8k)502.0k195.4k131.6k(1.1m)(1.5m)(2.0m)(164.7k)(260.3k)309.0k916.0k4.8m3.3m272.0k(3.7m)(3.0m)1.6m1.6m97.0k15.0k(4.6m)

Cash From Operating Activities

12.0m9.4m(4.8m)(4.2m)(6.3m)(4.0m)(6.9m)(9.4m)(3.9m)(6.8m)(12.1m)(4.6m)(7.2m)(8.8m)(1.8m)(4.1m)(5.3m)(3.5m)(5.5m)(9.7m)(6.7m)(16.2m)(18.9m)(6.1m)(12.7m)(18.9m)(6.3m)(13.3m)

Purchases of PP&E

(97.9k)(129.8k)(19.2k)(91.7k)(154.8k)(11.0k)(37.7k)(37.7k)(91.2k)(99.0k)(21.1k)(21.1k)(21.1k)(253.0k)(1.0m)(1.3m)(1.2m)(1.5m)(2.0m)(112.0k)(377.0k)(466.0k)(272.0k)(388.0k)

Cash From Investing Activities

(175.2k)(407.5k)(66.2k)(199.4k)(304.6k)(85.0k)(223.3k)(309.9k)(189.8k)(295.8k)(407.9k)(100.0k)(167.7k)(227.5k)(54.7k)(95.9k)(216.0k)(430.0k)(1.4m)(1.7m)(1.3m)(1.9m)(2.7m)(177.0k)(458.0k)(629.0k)(318.0k)(458.0k)

Long-term Borrowings

(7.0m)(7.0m)(7.0m)(2.5m)(21.7m)(21.7m)(21.7m)

Cash From Financing Activities

34.1k34.1k8.2m8.2m8.2m1.5k(41.5k)(41.5k)8.4m9.5m21.2m45.5k1.9m3.3m(1.6k)(1.6k)(7.0m)(7.0m)26.7m(250.0k)22.2m19.7m12.2m12.1m30.6m(206.0k)2.6m

Net Change in Cash

11.8m9.1m3.4m3.8m1.6m(4.1m)(7.1m)(9.7m)4.3m8.7m(4.6m)(5.4m)(5.7m)(1.9m)(4.2m)(5.6m)4.0m(2.0m)6.0m(1.1m)11.0m(6.9m)(11.2m)

Interest Paid

1.1m2.0m2.9m889.0k1.8m2.7m1.2m1.8m2.6m814.0k1.6m

Income Taxes Paid

1.6k1.6k1.6k1.6k1.6k1.6k1.6k1.6k1.6k1.6k1.6k1.6k1.6k1.6k1.6k178.0k14.0k42.0k36.0k32.0k132.0k7.0k13.0k

Apollo Endosurgery Ratios

USDQ2, 2011

Financial Leverage

6.7 x

Apollo Endosurgery Employee Rating

3.222 votes
Culture & Values
3.2
Work/Life Balance
3.3
Senior Management
2.9
Salary & Benefits
3.5
Career Opportunities
3
Source
View Apollo Endosurgery profile

Need Data?

Craft can deliver 250+ data points of financial, operating, and human capital indicators on companies via API.

Learn more